Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

CES 2025 is just around the corner, and our favorite companies are showing off their latest and greatest tech early. One of those companies is Solidd.

Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...